Gain of chromosome 17q correlates with high-stage disease, an adverse clinical outcome and leads to the overexpression of the antiapoptotic protein BIRC5/Survivin in neuroblastoma (NB). We have shown before that Survivin defines a threshold for the sensitivity of NB cells to DNA-damaging chemotherapeutic agents that require FOXO3 activation for apoptosis induction. To investigate the molecular basis of apoptosis inhibition we analyzed the function of Survivin at mitochondria and uncovered that Survivin induces mitochondrial fragmentation, reduces mitochondrial respiration and represses BCL2L11/Bim. Mitochondrial fission depends on Survivin-induced recruitment of the fission regulator DNM1L/Drp1 to mitochondria. In parallel, Survivin expression inhibits the respiratory complex-I, thereby preventing reactive oxygen species accumulation and, as a consequence, FOXO3-induced apoptosis. The loss of energy production via oxidative phosphorylation is compensated by increased glycolysis in Survivinoverexpressing NB tumor cells. Glycolysis inhibitors neutralize the antiapoptotic effect of Survivin and sensitize high-stage NB to DNA-damaging drugs. This suggests that glycolysis inhibitors target an 'archilles heel' of Survivin-overexpressing NB and may be highly useful as chemosensitizers in the treatment of high-stage NB.
INTRODUCTION
High-stage neuroblastoma (NB) is characterized by clinical diversity, which can be ascribed to different genetic alterations. The amplification of NMYC, 1 the gain of chromosome 17q, which encodes the apoptosis-inhibitor protein BIRC5/Survivin, 2 and hyperactive protein kinase B 3 are associated with a metastatic phenotype, chemotherapy resistance and poor prognosis. Active protein kinase B phosphorylates the transcription factor FOXO3 at serine-253 and threonine-308, causing its inactivation and export from the nucleus. 3, 4 When active, FOXO3 induces the proapoptotic BH3-only proteins BCL2L11/Bim and PMAIP/Noxa, loss of the membrane potential and release of cytochrome-c. 4 FOXO3 also represses Survivin and thereby sensitizes NB cells to DNAdamaging chemotherapeutic agents. 5 Recently, we demonstrated that apoptosis by FOXO3 depends on the biphasic accumulation of mitochondrial reactive oxygen species (ROS), which is regulated via a sequential induction of Bim and SESN3 in NB cells. 6 Mitochondrial function is regulated via changes in mitochondrial shape and size by proteins of the fusion/fission machinery. Among them, DNM1L/Drp1 induces mitochondrial fragmentation, whereas mitofusins (Mfn1 and Mfn2) in the outer mitochondrial membrane, as well as the protein optic atrophy-1 contribute to mitochondrial fusion. Together with pro-and antiapoptotic members of the BCL2 family, the fusion/fission machinery is associated with mitochondrial fragmentation and cytochrome-c release after apoptosis initiation. 7, 8 Mitochondrial connectivity is also linked to oxidative phosphorylation, 9 which is the main source of intracellular ATP production. Energy-rich NADH and FADH 2 are produced via oxidation of glucose and fatty acids and mediate the electron transfer to O 2 . This electron transfer takes place at a chain of four large enzyme complexes that controls the transport of protons across the inner mitochondrial membrane. The entry point of these electrons is complex I, the main mitochondrial source of ROS. 10 Mitochondrial respiration continuously leads to ROS production-up to 2% of consumed oxygen is converted to ROS. 11 Low levels of ROS serve as signaling molecules and mediate cellular proliferation via interaction with receptors, phosphatases, different tyrosine and serine/threonine kinases as well as transcription factors. 12, 13 High levels of ROS, however, cause DNA-, RNA-or lipid damages and contribute to apoptosis induction. Alternatively, energy can be obtained from cytosolic lactic fermentation, which converts glucose into lactate via reduction of pyruvate. Although 36 mol ATP per mol glucose are produced during aerobic respiration, this process generates only 2 mol ATP per mol glucose.
14 Most cancer cells produce high amounts of lactate, despite sufficient oxygen availability, a process known as 'Warburg effect' or 'aerobic glycolysis'. Thereby, about 4 mol ATP per mol glucose are generated, as only 5-10% pyruvate is metabolized via mitochondria. 15 Aerobic glycolysis prevents ROS accumulation 16 and disrupts T-cell metabolism and function. 17 Enhanced lactate levels induce the expression of hyaluronan, a glucosaminoglycan and its receptor CD44, thereby reducing cell adherence and promoting cancer invasion and metastasis.
Consequently, shifting energy production from oxidative phosphorylation to glycolysis facilitates cancer cells to invade the surrounding tissue, to evade immune attack and to proliferate under hypoxia. Similar to many other aggressive tumors 19 highstage NB show an increase of proteins involved in glycolysis. 20 As there is no correlation between NMYC amplification and Warburg effect 21 the underlying molecular mechanisms in high-stage NB are still unknown.
Here we report that Survivin prevents FOXO3-induced ROS formation and shifts energy production from mitochondrial respiration to aerobic glycolysis through reorganization of the mitochondrial network. Glycolysis inhibitors overcome Survivininduced therapy resistance, suggesting them as useful chemosensitizers in the treatment of high-stage NB.
RESULTS DNA-damaging agents cause repression of Survivin via FOXO3, which affects mitochondrial ROS production during apoptosis Increased Survivin expression rescues NB cells from FOXO3-induced apoptosis (Supplementary Figure S1a) and defines a sensitivity threshold to DNA-damaging agents such as etoposide and doxorubicin. 5 We demonstrated before that chemotherapeutic drugs activate FOXO3 6 and that FOXO3 represses Survivin (Supplementary Figure S1b) . 5 We therefore analyzed Survivin protein levels in epithelial-like SH-EP and neuronal-like, high-stage STA-NB15 cells after treatment with either etoposide or doxorubicin (Figure 1a ). Both agents lead to repression of Survivin; in SH-EP cells Survivin is repressed 4 h after etoposide and 8 h after doxorubicin treatment (left panels). In STA-NB15 cells Survivin levels decline 16 h after etoposide and 4 h after doxorubicin treatment (right panels). To explore whether the repression of Survivin by chemotherapeutic drugs involves FOXO3, we infected SH-EP and STA-NB15 cells with retroviruses or lentiviruses coding for a dominant-negative FOXO-DNA-binding domain (FOXO-DBD) or FOXO3-specific short-hairpin RNA (shRNA), respectively. 6, 22 FOXO3 inactivation by FOXO-DBD (Figure 1b) or FOXO3 knockdown (Supplementary Figure S2) delays Survivin repression during etoposide treatment, demonstrating that activation of FOXO3 by DNA-damaging agents contributes to the repression of Survivin.
Survivin was reported to partially localize to the mitochondria preventing mitochondria-dependent apoptosis. 23 In NB, significant amounts of Survivin are detected in the mitochondrial fraction (Supplementary Figure S3a) . To investigate the effect of Survivin on mitochondria, we analyzed, whether increased cellular levels of Survivin influence ROS production in response to FOXO3 activation. We therefore expressed Survivin in SH-EP/FOXO3 cells (SH-EP/FOXO3-Surv), activated FOXO3 by 4OHT and measured ROS accumulation by reduced MitoTracker Red (CM-H 2 XROS) staining. Consistent with our previous work FOXO3 induces a biphasic ROS accumulation in SH-EP/FOXO3-Ctr cells with a first peak at 4 h and a second ROS burst at 16 h (Figure 1c , upper panel). 6 Ectopic Survivin prevents FOXO3-induced ROS accumulation at both time points (Figure 1c , lower panel) and apoptosis induction (Supplementary Figure S1a) , but does not change the levels of total and soluble cytochrome-c (Supplementary Figure S3b) . The first ROS wave correlates with induction of Bim by FOXO3 and translocation of BAX to mitochondria, 6 which is both inhibited by Survivin. 5 The second ROS burst is associated with and possibly triggered by the oxidoreductase p66/SHC1 (Supplementary Figure S3c) . FOXO3 causes phosphorylation at serine-36 of p66/ SHC1 after 16 h correlating with the time point of the second ROS accumulation and apoptosis induction in SH-EP/FOXO3 cells. 4, 6 Survivin interferes with p66/SHC1 phosphorylation and the second ROS burst, suggesting that Survivin prevents ROS production in mitochondria. To confirm inhibition of mitochondrial ROS formation by Survivin, we treated SH-EP/Ctr and SH-EP/Surv cells with 100 mM H 2 O 2 and determined apoptosis induction by Figure S3d) . These results indicate that Survivin prevents mitochondrial ROS during FOXO3-induced apoptosis.
Survivin changes mitochondrial morphology, increases Drp1 and lowers Bim steady-state expression Dohi et al. 23 reported that the apoptosis-inhibiting function of Survivin depends on its partial localization to the mitochondria. As Survivin inhibits mitochondrial ROS accumulation and apoptosis with similar kinetics as the antiapoptotic FOXO3-target protein BCL2L1/BclxL, 6 we further investigated the effects of these two proteins on mitochondria. First, we analyzed mitochondrial morphology by CMXRos staining in SH-EP/Ctr, SH-EP/Surv and SH-EP/BclxL cells. SH-EP/Ctr and SH-EP/BclxL cells mainly possess network-like mitochondria throughout the cells (Figure 2a ). In cells with increased Survivin expression, however, mitochondria presented as punctuated, perinuclear structures, suggesting mitochondrial fission. Mitochondrial architecture is controlled by the balance of fission and fusion proteins. In mammals, Drp1 is the main regulator of mitochondrial fragmentation. Consequently, we compared the basal expression of Drp1 and Bim, which triggers ROS production after FOXO3 activation. 6 Figure 2b shows that both, ectopic Survivin and BclxL lead to increased Drp1 expression. In SH-EP/BclxL cells Bim protein was slightly elevated, probably because of increased sequestration by BclxL, whereas ectopic Survivin decreased endogenous Bim levels. This suggests a co-operation between Survivin and Drp1 in mitochondrial reorganization and Bim repression. As Survivin prevents FOXO3-induced apoptosis upstream of cytochrome-c release, 5 we analyzed regulation of critical fission and fusion proteins during FOXO3 activation.
Survivin prevents FOXO3-induced changes of mitochondrial fission/fusion regulators FOXO3 activation leads to a strong induction of Drp1, Mfn1 and Mfn2 within 24 h of 4OHT treatment, which correlates with the onset of apoptosis in these cells (Figure 2c , left panel) 4 and indicates reorganization of mitochondria. Both, ectopic Survivin and to a lesser extend BclxL, prevented the induction of these fusion/fission proteins after FOXO3 activation ( Figure 2c , middle and right panel). In contrast to BclxL, Survivin almost completely prevented Bim induction by FOXO3. Drp1 mediates mitochondrial fission during apoptosis by translocation from the cytoplasm to the mitochondria before cytochrome-c release. 24 In SH-EP/FOXO3 cells, FOXO3-induced cytochrome-c release starts already 8 h after 4OHT treatment and is clearly detectable 24 h after FOXO3 activation (Supplementary Figure S3a) . 4 To study the subcellular localization of Drp1 during FOXO3 activation and the effects of Survivin and BclxL on this process we treated SH-EP/FOXO3-Ctr, SH-EP/FOXO3-Surv and SH-EP/FOXO3-BclxL cells for 8 h with 4OHT and analyzed the cellular distribution of Drp1 by subcellular fractionation. Drp1 translocated to the mitochondria within 8 h Elevation of Survivin represses Bim and induces Drp1-dependent mitochondrial fission within 72 h To further investigate, whether Drp1 localization, mitochondrial fragmentation and Bim repression represent long-term effects of increased cellular Survivin, or if these changes are induced within a short period of time, we expressed Survivin in a tetracyclineregulated manner. 25 Induction of Survivin by doxycycline (doxy) leads to reduced Bim levels within 48 h (Figure 3a) , which is in line with the results from constitutively Survivin-expressing cells, where Bim levels were markedly decreased compared with controls ( Figure 2b ). To analyze whether Survivin induction contributes to mitochondrial fragmentation, we analyzed mitochondrial morphology by CMXRos-staining. As shown in Figure 3b , tetracycline-regulated Survivin changes mitochondrial architecture: 72 h after doxy treatment 56% of Survivin-expressing cells contain shortened mitochondria. Immunoblot analyses of mitochondrial fractions from doxy-treated SH-EP/tetSurv cells demonstrate that Survivin induces the accumulation of Drp1 at mitochondria within 48 h (Figure 3c ). To determine whether punctuate mitochondrial morphology depends on Drp1 activity in Survivin-overexpressing cells we treated SH-EP/Ctr and SH-EP/Surv cells with the Drp1-specific inhibitor Mdivi-1 or knocked down Drp1 by shRNA. Mdivi-1 treatment resulted in significant elongation of the mitochondrial network in SH-EP/Surv cells and increased mitochondrial connectivity from 10.7 to 54.1% after 36 h. In SH-EP/Ctr cells fragmentation was reduced from 15.7 to 8.2% (Figure 3d) . Consistent with the effect of the inhibitor Mdivi-1, the knockdown of Drp1 with different shRNAs overcame the Survivin-induced phenotype and induced mitochondrial fusion and elongation (Supplementary Figure S4a) . These experiments demonstrate that increased Survivin expression induces Survivin lowers mitochondrial respiration and prevents both, ROS accumulation and transitory repression of mitochondrial respiration by FOXO3 ROS production during mitochondrial respiration can cause damages that directly affect respiration capacity and ATP production. We recently demonstrated that FOXO3-induced ROS accumulation reduces respiration and is prevented by ectopic BclxL. 6 Oxidative phosphorylation and ATP production are tightly linked to mitochondrial connectivity and fragmentation. 26, 27 To determine whether mitochondrial fragmentation caused by Survivin affects respiration and cellular ATP levels we measured mitochondrial respiration in SH-EP/FOXO3-Ctr and SH-EP/FOXO3-Surv cells 4 and 8 h after FOXO3 activation. FOXO3 reduces uncoupled respiration to 72% compared with untreated controls (Po0.05) but respiration recovered to 99.8% after 8 h correlating with decreased ROS-levels after 8 h (Figures 1c and 4a) . Surprisingly, SH-EP/FOXO3-Surv cells showed only one third respiratory capacity of controls (Po0.001) and FOXO3 activation only slightly affected oxidative phosphorylation in these cells (Figure 4a) . Analyses of the individual complexes of the respiratory chain revealed that increased Survivin expression strongly reduced complex-I activity (Figure 4b ). To further investigate the effect of Survivin on single components we analyzed the main subunits of each respiratory complex. Immunoblot analyses of SH-EP/FOXO3-Ctr and SH-EP/FOXO3-Surv cells uncovered that complex-I and IV are almost absent in Survivin-expressing cells. Activation of FOXO3 by 4OHT increased the amount of complex-I, II and IV in controls but not in SH-EP/FOXO3-Surv cells, whereas complex-III and complex-V (ATP synthase) expression was not affected by FOXO3. The transitory decrease in mitochondrial respiration (Figure 4a ) is in contrast to the induction of complex-I, II and IV and might result from mitochondrial permeabilization by the pro-apoptotic protein Bim, as recently described. 6 The markedly reduced expression of complex-I is in agreement with lack of complex-I activity (Figure 4b ) and absence of ROS accumulation in SH-EP/FOXO3-Surv cells, suggesting complex-I as the main ROS source after FOXO3 activation. To assess whether Survivin directly affects respiratory complexes or whether these regulations are secondary to Drp1 recruitment to mitochondria, we analyzed the steady-state levels in Mdivi-1-treated and in Drp1-knockdown SH-EP/FOXO3-Surv cells. In parallel to the formation of mitochondrial networks (Figure 3d and Supplementary Figure S4a Figures  S4b and c) . This indicates that repression of complex-I and IV by Survivin results from Drp1-induced mitochondrial fission.
As no differences in cellular ATP levels were observed in SH-EP/ FOXO3-Ctr and SH-EP/FOXO3-Surv cells (Figure 4d , left panel) an alternative source of ATP production must exist in cells with increased cellular Survivin. ATP can also be produced by oxidation High Survivin expression shifts NB cell metabolism to aerobic glycolysis ATP production via glycolysis in the presence of oxygen is a hallmark of aggressive tumors and facilitates metastasis of cancer cells through acidification of the surrounding tissue via increased lactate production. In NB the increased expression of Survivin caused by the gain of chromosome 17q correlates with high-stage tumors, increased metastasis and therapy resistance. 2 As cells with increased Survivin levels metabolize glucose faster and produce more lactate than NB cells with low Survivin levels, we analyzed the glycolysis dependency of SH-EP/Surv cells. SH-EP/Ctr and SH-EP/Surv cells were treated with the glucose analog 2-deoxy-Dglucose (2DG), which cannot be metabolized to fructose-6-phosphate and thereby blocks glycolysis. Tetramethylrhodamine methyl ester (TMRM)-staining showed that SH-EP/Surv cells lose their mitochondrial potential and start to detach after 24 h (Figure 5a, lower panel) . In SH-EP/Ctr cells no morphological changes were visible and the mitochondrial potential was not affected by 2DG treatment (Figure 5a, upper panel) . This indicates that SH-EP/Surv cells depend on glycolysis to produce equivalent amounts of ATP compared with SH-EP/Ctr cells. Treatment with 2DG induced 30% apoptosis in SH-EP/Surv cells within 24 h (Po0.001), whereas SH-EP/Ctr cells remained unaffected (Figure 5b ). The hexokinase inhibitor lonidamine (LND) inhibits the conversion of glucose to glucose-6-phosphate and thereby blocks glycolysis upstream of 2DG. Both, 2DG and LND decreased viability of SH-EP/Surv cells to 28.5% and 23.6%, respectively (Po0.001; Figure 5c ). In SH-EP/Ctr cells viability was lowered to BIRC5/Survivin enhances aerobic glycolysis J Hagenbuchner et al only 77.5 and 73.7%, demonstrating that SH-EP/Ctr cells metabolize glucose more efficiently to produce ATP. To test whether knockdown of Survivin also changes sensitivity to glycolysis inhibitors we used STA-NB15 cells that express high levels of endogenous Survivin. As shown in Figure 5d , 2DG treatment reduced viability to 30% in STA-NB15 controls. However, the knockdown of endogenous Survivin conferred marked resistance and increased viability to 73% (P ¼ 0.0013). To exclude the protection of mitochondrial integrity in general sensitizes NB to glycolysis inhibition we also treated BclxL-expressing cells with 2DG. BclxL that exerts a similar apoptosis-protective effect as Survivin, but does not change mitochondrial architecture (Figure 2a) , did not affect the sensitivity to glycolysis inhibitors (Supplementary Figure S5a) . This indicates that increased sensitivity of Survivin-overexpressing NB cells to glycolysis inhibitors is directly connected to Survivin-induced changes in mitochondrial structure and metabolism.
Glycolysis inhibitors specifically sensitize Survivin-overexpressing NB cells to chemotherapeutic agents Next, we tested whether 2DG treatment neutralizes the antiapoptotic effect of Survivin. We therefore treated SH-EP/FOXO3-Ctr and SH-EP/FOXO3-Surv cells with a low dose of 2DG (2.5 mM) alone or in combination with low-dose 4OHT, etoposide or doxorubicin to activate FOXO3. 6 Ectopic Survivin protected cells from etoposide-, doxorubicin-or FOXO3-induced apoptosis, whereas in SH-EP/FOXO3-Ctr cells viability was reduced to 55% by 4OHT, to 69% by etoposide and to 68% by doxorubicin. However, 2DG treatment abrogated Survivin protection against FOXO3-induced apoptosis (Po0.01) (Figure 6 ). Similar results were achieved by co-treatment of 2DG with etoposide or doxorubicin when cell viability was reduced from 90% to 34% and 38% (Po0.001), respectively. Even a low dose of 0.1 mM 2DG lowered viability in combination with etoposide in Survivin-overexpressing tumor cells (Supplementary Figure S5c) . In comparison, neuronal PC12 cells did not respond to 15 mM 2DG alone or to a combination with etoposide, suggesting that non-transformed cells are not affected by 2DG (Supplementary Figure S5b) . This clearly demonstrates that Survivin confers glycolysis dependence and chemotherapy resistance in high-stage NB with 17q gain and that co-treatment with 2DG neutralizes this protective effect.
DISCUSSION
In the present study we demonstrate that the antiapoptotic protein Survivin reprograms cellular metabolism in NB cells by shifting energy production from oxidative phosphorylation to aerobic glycolysis. These changes are associated with reorganization of the mitochondrial network, which contributes to the antiapoptotic function of Survivin. We recently demonstrated that FOXO3-induced apoptosis depends on a biphasic mitochondrial ROS accumulation 6 and that FOXO3 represses Survivin and thereby regulates drug sensitivity.
5,28 Now, we further explored Survivin function during FOXO3-induced apoptosis and observed that ectopic Survivin prevented ROS accumulation during FOXO3 activation. Interestingly, Survivin interferes with both ROS waves, with the early wave by repressing Bim and the late wave, probably by inhibiting the phosphorylation of the oxidoreductase p66/SHC1 (Figure 1c and Supplementary Figure S3c) . The antiapoptotic function of Survivin has been ascribed to its mitochondrial localization. 29, 30 However, Survivin not only interferes with FOXO3-induced apoptosis, but induces striking changes of the mitochondrial network by recruiting the fission protein Drp1 to mitochondria (Figures 2a-d) . In parallel, Bim expression was reduced, which prevents FOXO3-induced uncoupling of mitochondrial respiration (Figure 4a ) and cytochrome-c release from mitochondria. 5 Interestingly, during FOXO3-induced apoptosis the expression of fission and fusion proteins increases. Mitochondrial accumulation of Drp1 might be triggered by the first FOXO3-induced ROS wave, as Drp1 was shown to translocate to the mitochondria after being dephosphorylated at serine-637 during oxidative stress. 31 However, Survivin which per se recruits Drp1 to the mitochondria (Figure 2d ) and promotes mitochondrial fission (Figure 2a) , prevents the induction of Mfn1, Mfn2 and Bim during FOXO3 activation (Figure 2c ). This ability of Survivin distinguishes its antiapoptotic effects from those of the BCL2 family member BclxL, which blocks apoptosis at mitochondria by sequestration of the BH3-only protein Bim, 6 but does not affect mitochondrial shape. Consistent with the results of Sheridan et al., 8 who described mitochondrial fission independent of cytochrome-c release and apoptosis, our data imply that Survivin-induced mitochondrial fission via Drp1 recruitment prevents apoptosis and reduces drug sensitivity. As mitochondrial connectivity correlates with ATP production we expected reduced ATP levels in Survivinexpressing cells. Survivin-overexpressing cells had ATP levels comparable to controls (Figure 4d, left) , but surprisingly showed significantly reduced respiratory activity, which was most likely due to an almost complete absence of complex-I and -IV (Figures 4b  and c) . As respiratory complex-I and -III are the main sources of cellular ROS the repression of complex-I by Survivin provides an explanation why these cells do not produce ROS during FOXO3-induced apoptosis, and are thereby resistant to several forms of One hallmark of aggressive, high-stage NB is the gain of chromosome 17q, which increases activity of the Survivin gene. 2 Aggressive tumors frequently produce most ATP by aerobic glycolysis and acidify their surrounding tissue by increased lactate production. This facilitates metastasis by suppression of immune cells as well as increased detachment of tumor cells. 17, 18 Indeed, Survivin overexpression significantly increases glucose consumption and lactate production (Figure 4d ) reflecting highly active glycolysis. The rate-limiting enzyme of glycolysis is 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase-3 (PFKFB3), which generates fructose-2-6-biphosphate. In neurons PFKFB3 levels are low due to high expression of the PFKFB3-specific E3-ubiquitine ligase APC/C-Cdh1. The overexpression of PFKFB3 in neuronal cells increases glycolysis and in parallel shuts down oxidative phosphorylation. 32, 33 We found APC/C-Cdh1 repressed and PFKFB3 induced in Survivin-expressing cells (Supplementary Figure S5d) explaining increased glycolytic activity (Figure 4d) . Interestingly, APC/C-Cdh1 is also the E3-ubiquitine ligase that is responsible for the degradation of nuclear Survivin. 34 This suggests a yet unidentified feedback regulation between Survivin/mitochondria and APC/C-Cdh1 that leads to increased PFKFB3 expression and promotes glycolysis. Survivin repression by FOXO3 causes mitochondrial fusion (data not shown) and reduces glucose consumption (Supplementary Figure S5e) . This effect can also be mimicked by knockdown of Drp1 (Supplementary Figure S4c) , suggesting that Drp1 acts downstream of Survivin. On the basis of these observations we hypothesized that high Survivin expression might sensitize cells to glycolysis inhibition. Consistent with this assumption we found that the glycolysis inhibitors LND and 2DG specifically induce death in Survivinoverexpressing cells (Figures 5c and d) . STA-NB15 cells which carry a gain of chromosome 17q are sensitive to 2DG-treatment but become resistant to 2DG-induced apoptosis when endogenous Survivin is knocked down by shRNA (Figure 5d ). These observations may explain data from Smith et al. 21 who showed that NMYC amplification does not correlate with increased glycolysis and that other mechanisms may be responsible. Our results are also therapeutically important as the hexokinase inhibitor LND is already in use in phase II and III clinical trials for breast, ovarian and non-small-cell lung carcinoma, 35, 36 and 2DG showed promising effects in combination with standard therapeutics for the treatment of glioblastoma multiforme patients. 37 We have described before that elevated Survivin expression in NB cells confers resistance to chemotherapeutic drugs such as etoposide and doxorubicin. 5 In this study, we provide evidence that DNA-damaging agents cause repression of Survivin via activation of the transcription factor FOXO3 (Figures 1a and b and Supplementary Figure S2) . However, when Survivin is overexpressed due to gain of chromosome 17q, it inhibits FOXO3-induced cell death by recruiting Drp1 and inducing mitochondrial fission, which changes energy metabolism. Low-dose treatment with 2DG overcomes this protection and sensitizes Survivinoverexpressing cells to FOXO3-and chemotherapeutic agentinduced apoptosis (Figure 6a) . For the first time we demonstrate that increased Survivin expression induces mitochondrial fragmentation, shuts down mitochondrial respiration and shifts energy metabolism from oxidative phosphorylation to aerobic glycolysis (schematic Figure 6b) , which contributes to chemotherapy resistance and might facilitate metastasis. Although protected against drug-induced apoptosis, Survivin-overexpressing tumors expose an 'archilles heel' as they become sensitive to glycolysis inhibitors. Our results therefore indicate glycolysis inhibitors as promising agents to overcome the chemotherapy-protective effects of Survivin in poor prognosis, high-stage NB.
MATERIALS AND METHODS

Cell lines, culture conditions, and reagents
The NB lines SH-EP, STA-NB15 and Phoenix packaging cells 38 were cultured in RPMI1640 (Lonza, Basel, Switzerland) containing 10% fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin (PAA, Pasching, Austria) and 2 mM L-glutamine (Lonza) at 5% CO 2 . HEK293T cells were cultured in Dulbecco's modified Eagle medium (Invitrogen, Carlsbad, CA, USA). All cultures were routinely tested for mycoplasma contamination using the Venor GeM-mycoplasma detection kit (Minerva Biolabs, Berlin, Germany).
Retroviral and lentiviral expression vectors pLIB-FOXO3(A3)-ER-iresNeo, pLIB-MCS2-iresPuro, pLIB-Survivin-iresYFP, pLIBrtTA-M2-iresTRSID-iresPuro, pLIB-BclxL-iresPuro, pQ-tetH1-SV40Puro, pSITVNeo, pLIB-mycTag-FOXO-DBD and lentiviral vectors coding for FOXO3-specific shRNA have been described previously. [4] [5] [6] 22, 25, 39 Drp1-specific shRNA lentiviruses were obtained from ThermoScientific (Waltham, MA, USA). For construction of pSITV-Survivin-Neo the Survivin-coding region was amplified from human cDNA and inserted into the BamH1-EcoRI sites of pSITV-Neo. Survivin-specific shRNA oligonucleotides containing the sequence 5 0 -GCATTCGTCCGGTTGCGCT-3 0 were cloned into the BamH1-Mun1 sites of pQ-tetH1-SV40-Puro.
Production of retroviruses and lentiviruses for infection of NB cells
Retro-and lentiviruses were produced as previously described. 6 SH-EP/ FOXO3-Ctr, SH-EP/Ctr, SH-EP/Surv, SH-EP/BclxL, SH-EP/FOXO3-Surv, SH-EP/ FOXO3-BclxL, SH-EP/tetCtr, SH-EP/FOXO3-shCtr, SH-EP/FOXO-DBD, NB15/ FOXO-DBD, SH-EP/shCtr, SH-EP/shFOXO3-17-clone7, NB15/shCtr and NB15/shFOXO3-17 cells have been described. [4] [5] [6] 39 pLKO.1 served as control (SH-EP/shCtr and NB15/shCtr). NB15/shSurv cells were generated by infection with the pQ-tetH1-shSurv vector, SH-EP/FOXO3-Surv-shDrp1 clones by infection with pLKO-shDrp1 vectors. For tetracycline-regulated gene expression, SH-EP cells were sequentially infected with pLIB-rtTAM2-ires-TRSID-iresPuro and pSITV-Survivin-Neo supernatants (SH-EP/tetSurv) or empty pSITV-Neo vector(SH-EP/tetCtr 25 ).
Subcellular fractionation and immunoblotting
For immunoblot analyses total protein or cytoplasmic and mitochondrial extracts were prepared as described previously. 6 Total protein (50 mg/lane) or cytoplasmic and mitochondrial fractions (10 mg/lane) were separated by SDS-polyacrylamide gel electrophoresis and blotted. Membranes were blocked, incubated with primary antibodies against BclxL, CoxIV, FOXO3 (Cell Signaling Technology Inc., Boston, USA), Bim, c-Myc, p66/SHC1 (BDPharmingen, Franklin Lakes, NJ, USA), Survivin (Upstate Biotechnology, Lake Placid, NY, USA), Drp1, MFN2, OXPHOS (Abcam, Cambridge, UK), MFN1 (Sigma-Aldrich, Vienna, Austria), pSer36-p66/SHC1 (Alexis Biochemicals, San Diego, CA, USA), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Acris, Herford, Germany) and a-Tubulin (Oncogene Research Products, La Jolla, San Diego, CA, USA), washed and detected with secondary horseradish peroxidase-conjugated antibodies. The blots were developed by enhanced chemiluminescence (GE-Healthcare, Vienna, Austria) and measured with an AutoChemi detection system equipped with LabWorks software (UVP, Cambridge, UK).
Live cell fluorescence microscopy
For live cell analyses cells were grown on LabTek Chamber Slides (Nalge Nunc International, ThermoScientific) coated with 0.1 mg/ml collagen. ROS measurements were performed by incubating the cells with MitoTracker Red CM-H 2 XROS (Invitrogen). Mitochondrial morphology was analyzed by CMXRos staining, mitochondrial potential was measured by TMRM staining, nuclei were stained with Hoechst stain. Images were collected using an Axiovert200M microscope equipped with an ApoTome.2 system (Zeiss, Vienna, Austria).
Flow cytometry
Apoptosis was assessed by staining the cells with propidium iodide or AnnexinV using a CytomicsFC-500 Beckman Coulter (Brea, CA, USA) as previously described. 5, 39 For measurement of AnnexinV positive cells 5 Â 10 5 cells were harvested and stained with APC-labeled AnnexinV (Alexis Biochemicals) in Annexin Binding Buffer. BIRC5/Survivin enhances aerobic glycolysis J Hagenbuchner et al
